Skip to content

Site logo

Main menu
  • Our impact
    • About us
    • Our mission, vision & values
    • Our leaders
  • Our products
    • Women’s health
    • Biosimilars
    • Established medicines
  • Media
  • Join our team

Contact us

Products

Change language

Twitter icon Linkedin icon

Back
Change Language
  • Français
Main menu
Organon site directory
  • The Americas
    • Organon
      Brazil
      Canada  English  ·  French
      CARD & Caribbean (Panama)
      Chile
      Colombia
      Ecuador
      Mexico
      Peru
      USA
  • Europe
    • Organon
      Austria
      Belgium  Dutch  ·  English
      Czech Republic  Czech  ·  English
      Denmark
      Finland
      France
      Germany
      Ireland
      Italy
      Luxembourg
      Netherlands  Dutch  ·  English
      Norway
      Portugal
      Spain
      Sweden
      Switzerland
      United Kingdom
  • Asia Pacific
    • Organon
      Australia
      Indonesia
      Japan
      Malaysia
      New Zealand
      Philippines
      Singapore
      South Korea
      Thailand
      Vietnam
  • Middle East & Africa
    • Organon
      Turkey
View all locations and contact information

What can we help you find?

Search for:
woman on computer

Media

Our latest news

Press Releases

November 8, 2021

NEXPLANON® now covered by Quebec’s public formulary

September 22, 2021

Organon wants to help women take control of their birth control

June 21, 2021

Organon Canada Launches as New Women’s Health Company

Contact Our Media Team

cellphone

For media related inquiries about Organon Canada or our products,
please contact our Media Centre at:

1-450-366-1740
media_canada@organon.com

Connect with us on social

Linkedin icon Twitter icon
Site logo
  • About us
  • Our leaders
  • Our products
  • Media
  • Contact information
  • Join our team
  • Cookie Policy
  • Cookie Preferences
  • Terms of Use
  • Privacy Policy
  • Sitemap
Copyright © 2021 Organon group of companies. All rights reserved.
CA-NON-110126

You are leaving Organon.com

Cancel Continue

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept